| Date | Title | Description |
| 22.07.2026 | New Phase Appoints Renowned U.S. Cancer Expert Prof. Jeff Geschwind to Scientific Advisory Board for Oncology Treatment | A leading expert in interventional oncology and radiology, Prof. Geschwind will join New Phase in FDA discussions and support preparations for feasibility studies
MINNEAPOLIS, July 22, 2026 /PRNewswire-PRWeb/ -- New Phase, a clinical-stage ... |
| 22.06.2026 | HistoSonics Closes Funding | HistoSonics, a Minneapolis, MN-based medical device company developing the Edison Histotripsy System and new histotripsy therapy platforms, closed new funding.
The amount of the deal was not disclosed.
Backers included Reed Jobs and Yosemit... |
| 22.06.2026 | HistoSonics Announces Financing At $3.75 Billion Valuation For Histotripsy Therapy Platforms | HistoSonics announced the closing of a new financing round with participation from Reed Jobs and Yosemite, along with several new strategic investors. The financing values the company at $3.75 billion. Additional financing terms were not di... |
| 03.04.2026 | No Scalpel, No Radiation: Advanced Urology Brings Histotripsy to Atlanta, Transforming the Treatment of Kidney Cancer | Advanced Urology founder Dr. Jitesh Patel brings histotripsy to Atlanta — a non-invasive, scalpel-free breakthrough for kidney cancer now available in Georgia.
Our patients deserve the world's best care, not just Atlanta's best. Histotripsy... |
| 20.10.2025 | HistoSonics reels in $250M in funding 2 months after syndicate takes major stake | Cancer treatment developer HistoSonics reeled in $250 million in an oversubscribed series D round of financing two months after a syndicate of more then a dozen investors took a majority stake in the medtech as part of a deal valued at $2.5... |
| 18.10.2025 | HistoSonics Secures $250M: Accelerating Non-Invasive Tumor Therapy Worldwide | HistoSonics secured $250 million in growth financing. This capital propels the global commercial expansion of its Edison Histotripsy System. The system offers a revolutionary non-invasive therapeutic ultrasound technology. It precisely liqu... |
| 17.10.2025 | HistoSonics: $250 Million Growth Financing Raised For Improving Non-Invasive Tumor Therapy | HistoSonics, the developer of the Edison Histotripsy System and pioneer of the world’s first non-invasive histotripsy therapy platform, has closed an oversubscribed $250 million growth financing round. The funding, led by the company’s new ... |
| 16.10.2025 | HistoSonics Nabs $250M |
MINNEAPOLIS, MN, HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing round.
>> Click here for more funding data... |
| 16.10.2025 | HistoSonics Closes $250M Financing | HistoSonics, Inc., an Ann Arbor, MI and Minneapolis, MN-based developer of the Edison® Histotripsy System and novel histotripsy therapy platform, closed a $250m financing.
x
Please enable JavaScript
Video Player is loading.Play Video
Play
U... |
| 14.09.2025 | Venture Investors Health Fund: $80 Million Closing Of Seventh Fund | Venture Investors Health Fund, one of the Midwest’s longest-standing healthcare-focused venture capital firms, has closed its seventh fund with $80 million in committed capital. The new fund will be used to invest in early-stage healthcare ... |
| 18.08.2025 | Hatteras Venture Partners: Over $200 Million Raised For Two Healthcare Funds | Hatteras Venture Partners has announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I), securing over $200 million in capital commitments from limited partners. This milestone coinc... |
| 15.08.2025 | HistoSonics Valued at $2.25B After Major Acquisition to Accelerate Histotripsy Growth | What You Should Know:
– HistoSonics, the company behind the non-invasive Edison® Histotripsy System, has announced a management-led majority stake acquisition by a syndicate of private and public investors, including K5 Global, Bezos Expedi... |
| 11.08.2025 | HistoSonics: Univ. Of Michigan Spin-Out Sells Majority Stake In $2.25 Billion Deal | HistoSonics, creator of the Edison Histotripsy System, has been acquired in a majority stake deal by global investors including K5 Global, Bezos Expeditions, and Wellington Management, valuing the company at $2.25 billion. Additional invest... |
| 04.04.2025 | Li Ka Shing Foundation and Temasek Trust Jointly Commit S$12 Million to Acquire Systems and Advance Clinical Trial for Innovative Histotripsy Cancer Therapy in Singapore | Li Ka Shing Foundation (LKSF) and Temasek Trust (TT) are purchasing and donating two Histotripsy Systems to the National Cancer Centre Singapore (NCCS) and the National University Cancer Institute, Singapore (NCIS) in Singapore to perform c... |
| 15.03.2025 | Bridging Continents: The Future of UK-East Asia Education Partnerships | In a world increasingly defined by global connections, education serves as a bridge. The British Council East Asia Education Week 2025, held in Hong Kong from March 5 to 7, exemplifies this notion. It gathered educational leaders from the U... |
| 14.03.2025 | Bowtie and Gleneagles Hospital Hong Kong Collaborate to Upgrade VHIS Rider to Include Histotripsy Treatment In "Bowtie & Gleneagles Hospital Wellness Package" | Swift inclusion of innovative liver tumor treatment technology, lowers barriers for Hongkongers to access advanced medical services
HONG KONG, March 14, 2025 /PRNewswire/ -- Bowtie, Hong Kong's first virtual insurer[1], collaborates with Gl... |
| 19.12.2024 | HistoSonics non-invasive tumor destruction featured in Reuters Global Health Documentary Series | MINNESOTA, MN, UNITED STATES, December 19, 2024 /EINPresswire.com/ -- HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, released today a short documentary as part of Reuters Global Heal... |
| 21.08.2024 | HistoSonics: A New Dawn in Non-Invasive Cancer Treatment | In the world of medical technology, innovation is the lifeblood that fuels progress. HistoSonics, a pioneer in non-invasive cancer treatment, has recently secured $102 million in Series D funding. This investment is not just a financial boo... |
| 20.08.2024 | HistoSonics: $102 Million (Series D) Raised To Scale Non-Invasive Histotripsy Platform | HistoSonics, a manufacturer of the Edison Histotripsy System and novel histotripsy therapy platforms, announced the completion of an oversubscribed $102 million Series D financing. This funding round was led by Alpha Wave Ventures, a world ... |
| 15.08.2024 | HistoSonics Raises $102M in Series D Financing | HistoSonics, a Minneapolis, MN-based manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, closed $102m Series D financing.
The round was led by Alpha Wave Ventures, with participation from new investors Am... |
| 15.08.2024 | HistoSonics Secures $102M to Advance Non-Invasive Liver Tumor Treatment | What You Should Know:
– HistoSonics, a medical technology company specializing in histotripsy, a non-invasive treatment for liver tumors raises $102M in Series D financing round.
– Led by Alpha Wave Ventures, with participation from new inv... |
| 15.08.2024 | HistoSonics Receives $102M Series D |
MINNEAPOLIS, MN, HistoSonics announced today the completion of an oversubscribed $102 million Series D financing.
>> Click here for more funding data on HistoSonics
>> To export HistoSonics funding data to PDF and Excel, click ... |
| 15.08.2024 | HistoSonics Raises $102 Million for Liver Cancer Treatment | - |
| 15.08.2024 | HistoSonics nets $102M to boost its sound beam-powered liver cancer therapy | After collecting a de novo clearance from the FDA last fall for its ultrasound-powered liver cancer treatment, HistoSonics has raised $102 million in funds to turn up the volume on its commercial efforts.
The company’s Edison system uses th... |
| 09.01.2024 | World’s First Patients Treated With Novel Edison® Histotripsy System | HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System, announced today a patient from the University of Rochester Medical Center has received the world’s first targeted liver tumor treatments ut... |
| 10.10.2023 | FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System | HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy platforms, announced today the marketing authorization of its “Breakthrough” platform via the U.S. Food and Drug Administration’s (FDA... |
| 05.04.2023 | HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy | HistoSonics, (www.histosonics.com), the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the first kidney patient has been treated using the Company’s histotripsy platform. The procedure ... |
| 30.03.2023 | HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy | Leeds Teaching Hospitals NHS Trust, (UK) Performs Non-Invasive Histotripsy in Patient with Primary Solid Renal Tumor
MINNEAPOLIS, March 30, 2023 /PRNewswire/ -- HistoSonics, (www.histosonics.com), the developer of a non-invasive platform an... |
| 14.12.2022 | HistoSonics Raises $100M in Financings | HistoSonics, an Ann Arbor, Michigan and Minneapolis, MN-based developer of a non-invasive, novel sonic beam therapy, raised $100M in equity and debt.
The $85M equity round was led by Johnson & Johnson Innovation with participation from ... |
| 13.12.2022 | HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors | Financings Planned to Support Rapid Expansion of Histotripsy Platform as Company Welcomes Silk Road Medical CEO, Erica Rogers, to its Board of Directors
MINNEAPOLIS, Dec. 13, 2022 /PRNewswire/ -- HistoSonics, Inc. (www.histosonics.com), the... |
| 19.09.2022 | HistoSonics Announces Published Results of Phase I Liver Tumor Trial | As Company Advances Planning for FDA Submission and Future Growth
MINNEAPOLIS, Sept. 19, 2022 /PRNewswire/ -- HistoSonics, (www.histosonics.com), the developer and manufacturer of a completely non-invasive platform and proprietary sonic bea... |
| 01.06.2022 | HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies | Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy |
| 31.05.2022 | HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies | Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy
MINNEAPOLIS, May 31, 2022 /PRNewswire/ -- HistoSonics, (www.histosonics.com), the developer and manufacturer of a non-invasive platform a... |
| 24.05.2022 | HistoSonics Announces Agreement with GE Healthcare | MINNEAPOLIS, May 23, 2022 — HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare’s LOGIQ E10 Series ultrasound imag... |
| 12.07.2021 | American Medical Association (AMA) issued the first ever, unique CPT code for histotripsy of the liver | HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, today announced that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code f... |
| 02.02.2021 | HistoSonics Announces First Patient Treated in US Clinical Study of Novel Sonic Beam Therapy for Liver Tumors | |
| 11.01.2021 | HistoSonics Receives Approval To Begin European #HOPE4LIVER Clinical Study | |
| 05.10.2020 | HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study | |
| 09.09.2020 | HistoSonics Appoints Dr. Joe Amaral to Position of Vice President of Medical Affairs | |
| 09.06.2020 | Non-Invasive Robotic Platform Company HistoSonics Raises $40 Million | HistoSonics — the developer of a non-invasive robotic platform and sonic beam therapy — announced that it raised $40 million
HistoSonics — the developer of a non-invasive robotic platform and sonic beam therapy — announced that it raised $4... |
| 08.06.2020 | HistoSonics Raises $40M in Series C-1 Financing | HistoSonics, an Ann Arbor, MI. and Minneapolis, MN.-based developer of a non-invasive robotic platform and sonic beam therapy, closed a $40m Series C-1 financing.
The round was led by Yonjin Venture, LLC, with participation from existing in... |
| 08.06.2020 | HistoSonics Announces $40 Million Financing | Breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors |
| 08.06.2020 | HistoSonics Lands $40M Series C-1 To Perfect Precision Therapy | 9 Shares Email Facebook Twitter LinkedIn
HistoSonics closed on an oversubscribed $40 million in Series C-1 financing, led by Yonjin Venture LLC, to advance its technology that targets specific tissue, helping patients recover and heal more ... |
| 08.06.2020 | HistoSonics Lands $40M Series C-1 To Perfect Precision Therapy | 11 Shares Email Facebook Twitter LinkedIn
HistoSonics closed on an oversubscribed $40 million in Series C-1 financing, led by Yonjin Venture LLC, to advance its technology that targets specific tissue, helping patients recover and heal more... |
| 08.06.2020 | Cancer-fighting medical device startup Histosonics raises $40M | Histosonics, a medical technology company creating a non-invasive device that destroys cancerous tissue, has closed on $40 million in an oversubscribed Series C round of funding.
The round was led by Yonjin Venture, a firm investing in earl... |
| 08.06.2020 | HistoSonics Announces $40 Million Financing | - |
| 15.01.2020 | HistoSonics Leads The Observer’s 2020 List of Innovative Healthcare Companies | PLYMOUTH, Minn. /PRNewswire/ — HistoSonics, developer of a novel non-invasive sonic beam therapy platform, was named by The Observer as one of the nation’s most influential healthcare companies during the 38th J.P. Morgan Healthcare Investm... |
| 13.01.2020 | Flannel Is the New Black at the 2020 J.P. Morgan Healthcare Conference | The J.P. Morgan Healthcare Conference has positioned itself as not only the first, but perhaps the most important event of the global health care conference calendar year. Motionette
On Monday, January 13, like a swarm of honey bees, thousa... |
| 06.01.2020 | HistoSonics Receives 2019 Frost & Sullivan Technology Innovation Award | SAN ANTONIO /PRNewswire/ — Frost & Sullivan, a leading global research and analysis firm, announced that it has awarded HistoSonics its prestigious 2019 North American Technology Innovation Award for the development of the company’s new... |
| 12.06.2019 | HistoSonics Touts First-in-Human Study Results | HistoSonics announced its non-invasive robotics platform and novel sonic beam cancer therapy successfully destroyed 11 tumors in eight patients during its first clinical trial. |
| 15.04.2019 | Ann Arbor-Based Robotics Company HistoSonics Raises $54 Million | HistoSonics, an Ann Arbor, Michigan-based non-invasive robotics platform company announced it has raised $54 million in Series C funding. This round of funding was led by Varian Medical Systems —- a global leader in radiation therapy and on... |
| 11.04.2019 | HistoSonics Grabs $54M Series C |
ANN ARBOR, MI, HistoSonics, developer of a non-invasive robotics platform and novel beam therapy, announced today that it has closed a $54 million Series C financing.
>> Click here for more funding data on HistonSonics
>> To... |
| 11.04.2019 | Insurance Tech Startup Lemonade Raises $300 Million in Funding: Term Sheet for Thursday, April 11 | MAKING LEMONADE
Softbank is doubling down on Lemonade.
Paid Content You can't secure what you can't see From ExtraHop
Here’s how Fortune described the startup in 2016: It pools insurance premiums from people who know and trust one another. ... |
| 11.04.2019 | Daily funding roundup - April 11th, 2019 | Shedul.com landed $20M; Affectiva secured $26M; Mavenlink raised $48M; HistoSonics received $54M
Fauna Bio: Fauna Bio is a biotechnology company leveraging the science of hibernation to improve healthcare for humans. Fauna Bio has raised $4... |
| 08.04.2019 | HistoSonics Closes $54M Series C Financing | HistoSonics, an Ann Arbor, Mich.- and Minneapolis, MN-based developer of a non-invasive robotics platform and novel beam therapy, closed a $54m Series C financing.
The round was led by Varian Medical Systems, Inc., with participation from J... |
| 08.04.2019 | HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing | ANN ARBOR, MICHIGAN // Apr. 8, 2019 – HistoSonics, developer of a non-invasive robotics platform and novel beam therapy, announced today that it has closed a $54 million Series C financing. The round was led by Varian Medical Systems, Inc.,... |
| 08.04.2019 | HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing | - |
| 24.04.2017 | HistoSonics Aims To Move Forward After Raising $8.5M, Naming New CEO | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Changes are afoot at HistoSonics, the University of Michigan medical device spinout based in Ann Arbor, MI.
The company has a new CEO, as well as a new focus on the treatment ... |
| 03.09.2015 | HistoSonics Closes $3M Bridge Financing | HistoSonics, an Ann Arbor, MI-based non-invasive, image-guided therapeutic ultrasound, closed a $3m bridge financing round.
Backers included Grand Angels, a Grand Rapids, Mich.-based investment group.
The company intends to use the funds to... |
| 22.07.2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| 23.05.2014 | HistoSonics pulls in $14M | Medtech funding for the week of May 19, 2014 | HistoSonics nears close of $14.2M funding for non-invasive ablation May 20, 2014 by Arezu Sarvestani
Michigan medical device maker HistoSonics is creeping toward the close of a $14.22 million funding round in support of its non-invasive tis... |
| 20.05.2014 | HistoSonics nears close of $14.2M funding for non-invasive ablation | Michigan medical device maker HistoSonics is creeping toward the close of a $14.22 million funding round in support of its non-invasive tissue ablation technology.
The company has raised about $14.17 million so far from 13 unnamed investors... |
| 01.09.2010 | Ex-FDA commissioner joins board of Michigan cancer treatment firm | HistoSonics Inc. brought former Food & Drug Administration commissioner Dr. Andrew von Eschenbach onto its board yesterday.
The ex-commissioner’s experience as a surgeon, urological oncologist and healthcare administrator made him a goo... |
| 05.01.2010 | Michigan’s HistoSonics grabs $11M for prostate-disease-fighting device | The $11 million Series A financing is led by Venture Investors of Ann Arbor and Madison, Wis., according to the statement.
While most ultrasound products on the market use heat to destroy unwanted tissue, HistoSonics’ device uses cavitatio... |
| - | HistoSonics | “HistoSonics® is developing a non-invasive, robotically assisted platform capable of destroying tissue at a sub-cellular level.” |
| - | Michigan’s HistoSonics grabs $11M for prostate-disease-fighting device | ANN ARBOR, Michigan — University of Michigan spin-off HistoSonics Inc. has secured $11 million in financing to develop a device that uses ultrasound pulses to treat prostate disease, according to a statement from the University.
The company... |
